Literature DB >> 20194224

Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus.

Keiko Myouzen1, Yuta Kochi, Kenichi Shimane, Keishi Fujio, Tomohisa Okamura, Yukinori Okada, Akari Suzuki, Tatsuya Atsumi, Satoshi Ito, Kazuki Takada, Akio Mimori, Shiro Ikegawa, Ryo Yamada, Yusuke Nakamura, Kazuhiko Yamamoto.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease induced by the combinations of environmental and genetic factors. Recently, mice in which the early growth response 2 (EGR2) gene, a zinc-finger transcription factor, is conditionally knocked out in CD2(+) T cells have been shown to develop a lupus-like autoimmune disease. Here, we evaluated if polymorphisms in the EGR2 gene influence SLE susceptibility in humans. We first analyzed the effect of SNPs in the EGR2 region on EGR2 expression, and a significant positive correlation with expression was identified in an SNP located at the 5' flanking region of EGR2 (rs10761670, R=0.23, P=0.00072). We then performed a case-control association study using three sets of SLE cohorts by genotyping 14 tag SNPs in the EGR2 gene region. A peak of association with SLE susceptibility was observed for rs10761670 [Pooled: OR = 1.23 (95% CI 1.10-1.37), P=0.00023). This SNP was also associated with susceptibility to rheumatoid arthritis (RA) [OR = 1.15 (95% CI 1.05-1.26), P = 0.0019), suggesting that EGR2 is a common risk factor for SLE and RA. Among the SNPs in complete linkage disequilibrium with rs10761670 (r(2) = 1.0), two SNPs (rs1412554 and rs1509957) affected the binding of transcription factors and transcriptional activity in vitro, suggesting that they may be candidates of causal regulatory variants in this region. Therefore, EGR2 is a genetic risk factor for SLE, in which increased gene expression may contribute to SLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194224     DOI: 10.1093/hmg/ddq092

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Genetics of autoimmune diseases: perspectives from genome-wide association studies.

Authors:  Yuta Kochi
Journal:  Int Immunol       Date:  2016-02-08       Impact factor: 4.823

Review 3.  EGR-mediated control of STIM expression and function.

Authors:  Christina K Go; Scott Gross; Robert Hooper; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2018-12-06       Impact factor: 6.817

4.  The roles of Egr-2 in autoimmune diseases.

Authors:  Min Zhang; Ying Wang; Jian-Shu Wang; Jiao Liu; Meng-Meng Liu; Hai-Bing Yang
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

5.  Triggering receptor expressed on myeloid cells 1 (TREM-1)-mediated Bcl-2 induction prolongs macrophage survival.

Authors:  Zhihong Yuan; Mansoor Ali Syed; Dipti Panchal; Myungsoo Joo; Marco Colonna; Mark Brantly; Ruxana T Sadikot
Journal:  J Biol Chem       Date:  2014-04-07       Impact factor: 5.157

6.  Variants in ZNF365 isoform D are associated with Crohn's disease.

Authors:  Talin Haritunians; Michelle R Jones; Dermot P B McGovern; David Q Shih; Robert J Barrett; Carrie Derkowski; Marla C Dubinsky; Debra Dutridge; Phillip R Fleshner; Andrew Ippoliti; Lily King; Esther Leshinsky-Silver; Arie Levine; Gil Y Melmed; Emebet Mengesha; Eric A Vasilauskas; Shabnam Ziaee; Jerome I Rotter; Stephan R Targan; Kent D Taylor
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

7.  TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses.

Authors:  Tomohisa Okamura; Shuji Sumitomo; Kaoru Morita; Yukiko Iwasaki; Mariko Inoue; Shinichiro Nakachi; Toshihiko Komai; Hirofumi Shoda; Jun-Ichi Miyazaki; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Nat Commun       Date:  2015-02-19       Impact factor: 14.919

8.  Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production.

Authors:  Kaoru Morita; Tomohisa Okamura; Mariko Inoue; Toshihiko Komai; Shuzo Teruya; Yukiko Iwasaki; Shuji Sumitomo; Hirofumi Shoda; Kazuhiko Yamamoto; Keishi Fujio
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-30       Impact factor: 11.205

Review 9.  Therapeutic potential of regulatory cytokines that target B cells.

Authors:  Keishi Fujio; Tomohisa Okamura; Shuji Sumitomo; Kazuhiko Yamamoto
Journal:  Int Immunol       Date:  2015-12-08       Impact factor: 4.823

10.  SuRFing the genomics wave: an R package for prioritising SNPs by functionality.

Authors:  Niamh M Ryan; Stewart W Morris; David J Porteous; Martin S Taylor; Kathryn L Evans
Journal:  Genome Med       Date:  2014-10-14       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.